Off-label use of Amplatzer Duct Occluder II additional sizes
Conclusion: In our case series, ADO II-AS was well tolerated, versatile and cost-effective in treatment of different types of nonduct shunt lesions, mainly in young children and in older patients with comorbidities.
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Research articles: Valve disease Source Type: research
More News: Atrial Septal Defect | Bleeding | Cardiology | Cardiovascular | Children | Heart | Hole in the Heart | Ventricular Septal Defect